Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04978818 · ClinicalTrials.gov registry record · Phase 4
Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)
A Phase 4 study, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 333
- Enrollment target
NCT04978818 is a Phase 4 study that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 333 participants.
The verdict
NCT04978818, a Phase 4 study, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 333 participants
- Enrollment target
Study Summary
The main goal of this study is to compare the Haemophilus influenzae type b antibody response in American Indian / Alaska Native (AI/AN) infants to two licensed vaccines: Vaxelis and PedvaxHIB.
Interventions
- DRUG Vaxelis
- DRUG PedvaxHIB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2022-01-27 |
| Est. Completion | 2023-10-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04978818
The ClinicalTrials.gov registry entry for NCT04978818 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 333 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins Bloomberg School of Public Health, which has 187 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vaxelis is the first listed.
NCT04978818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04978818 about?
NCT04978818 is a clinical study titled "Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)". The main goal of this study is to compare the Haemophilus influenzae type b antibody response in American Indian / Alaska Native (AI/AN) infants to two licensed vaccines: Vaxelis and PedvaxHIB.
What is the current status of trial NCT04978818?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 333 participants. The study started on 2022-01-27. Estimated completion is 2023-10-26.
What interventions are being tested in trial NCT04978818?
The interventions under investigation include: Vaxelis (DRUG), PedvaxHIB (DRUG).
Who is sponsoring clinical trial NCT04978818?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.